Bispecific Claudin 18.2/TGF-β CAR Tcell therapy(ImmPACT Bio)

N/A

Report date: 2024/04/23 13:52:28

Base Information

Drug NameBispecific Claudin 18.2/TGF-β CAR Tcell therapy(ImmPACT Bio)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionClaudin 18 protein modulatorsTGF-β pathway modulators

TargetsClaudin-18 splice variant 2

Therapy Area/IndicationsStomach NeoplasmsEsophageal Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesImmPACT Bio USA Inc

China Registration ClassN/A

Develop Information

Active CompaniesImmPACT Bio USA Inc

Inactive CompaniesN/A

Active IndicationsStomach NeoplasmsEsophageal Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A